In case you missed these February headlines, here are 5 stories from around the Web of interest to primary care.
We have asked our editorial advisory board members to send us a story each month in 2016 that they find of particular interest. The content could have scientific, medical, or simply human-interest value. We curated their entires, added a few of our own, and the January result is the short slide show above. Here's a wrap up of randomly selected medical stories that have been making the headlines this month. - See more at: http://www.consultantlive.com/articles/6-top-primary-care-stories-month#...Did you miss any of these headlines? Find links to the sources below.- See more at: http://www.consultantlive.com/articles/7-top-primary-care-stories-month#sthash.yyPRVc0D.dpufWe have asked our editorial advisory board members to send us a story each month in 2016 that they find of particular interest. The content could have scientific, medical, or simply human-interest value. We curated their entires, added a few of our own, and the February result is the short slide show above.For more information on these stories, follow links below: Origins of Zika ⺠How a Medical Mystery in Brazil Led Doctors to ZikaPPIs Associated with Dementia Risk⺠Association of proton pump inhibitors with risk of dementiaLaw Limits Doctors’ Gun Speech⺠Battle rages over Florida law limiting doctors' gun speechLife-expectancy Gap Gets Wider ⺠What Growing Life Expectancy Gaps Mean for the Promise of Social Security (Brookings) ⺠Disparity in Life Spans of the Rich and the Poor Is Growing (NYT) Patients Don’t Share Genetic Test Results ⺠Consumer Perceptions of Interactions With Primary Care Providers After Direct-to-Consumer Personal Genomic Testing ⺠Medpage Today Video InterveiwWhen black holes collide⺠Gravitational waves: breakthrough discovery after a century of expectationÂ
Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting
October 14th 2024Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.